Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Novel insights into the pathogenesis of T-cell lymphomas.

Van Arnam JS, Lim MS, Elenitoba-Johnson KSJ.

Blood. 2018 May 24;131(21):2320-2330. doi: 10.1182/blood-2017-11-764357. Epub 2018 Apr 17. Review.

PMID:
29666117
2.

Clinical implications of oncogenic mutations in pulmonary Langerhans cell histiocytosis.

Brown NA, Elenitoba-Johnson KSJ.

Curr Opin Pulm Med. 2018 May;24(3):281-286. doi: 10.1097/MCP.0000000000000470.

PMID:
29470255
3.

Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.

Schrader A, Crispatzu G, Oberbeck S, Mayer P, Pützer S, von Jan J, Vasyutina E, Warner K, Weit N, Pflug N, Braun T, Andersson EI, Yadav B, Riabinska A, Maurer B, Ventura Ferreira MS, Beier F, Altmüller J, Lanasa M, Herling CD, Haferlach T, Stilgenbauer S, Hopfinger G, Peifer M, Brümmendorf TH, Nürnberg P, Elenitoba-Johnson KSJ, Zha S, Hallek M, Moriggl R, Reinhardt HC, Stern MH, Mustjoki S, Newrzela S, Frommolt P, Herling M.

Nat Commun. 2018 Feb 15;9(1):697. doi: 10.1038/s41467-017-02688-6.

4.

A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment.

Awasthi A, Rolland DCM, Ayello J, van de Ven C, Basrur V, Conlon K, Fermin D, Barth MJ, Klein C, Elenitoba-Johnson KSJ, Lim MS, Cairo MS.

Oncotarget. 2017 Dec 9;8(69):113895-113909. doi: 10.18632/oncotarget.23040. eCollection 2017 Dec 26.

5.

A metabolic function of FGFR3-TACC3 gene fusions in cancer.

Frattini V, Pagnotta SM, Tala, Fan JJ, Russo MV, Lee SB, Garofano L, Zhang J, Shi P, Lewis G, Sanson H, Frederick V, Castano AM, Cerulo L, Rolland DCM, Mall R, Mokhtari K, Elenitoba-Johnson KSJ, Sanson M, Huang X, Ceccarelli M, Lasorella A, Iavarone A.

Nature. 2018 Jan 11;553(7687):222-227. doi: 10.1038/nature25171. Epub 2018 Jan 3.

6.

Human papillomavirus (HPV) and somatic EGFR mutations are essential, mutually exclusive oncogenic mechanisms for inverted sinonasal papillomas and associated sinonasal squamous cell carcinomas.

Udager AM, McHugh JB, Goudsmit CM, Weigelin HC, Lim MS, Elenitoba-Johnson KSJ, Betz BL, Carey TE, Brown NA.

Ann Oncol. 2018 Feb 1;29(2):466-471. doi: 10.1093/annonc/mdx736.

PMID:
29145573
7.

New Insights into Lymphoma Pathogenesis.

Elenitoba-Johnson KSJ, Lim MS.

Annu Rev Pathol. 2018 Jan 24;13:193-217. doi: 10.1146/annurev-pathol-020117-043803. Epub 2017 Nov 15.

PMID:
29140757
8.

RBPJ/CBF1 interacts with L3MBTL3/MBT1 to promote repression of Notch signaling via histone demethylase KDM1A/LSD1.

Xu T, Park SS, Giaimo BD, Hall D, Ferrante F, Ho DM, Hori K, Anhezini L, Ertl I, Bartkuhn M, Zhang H, Milon E, Ha K, Conlon KP, Kuick R, Govindarajoo B, Zhang Y, Sun Y, Dou Y, Basrur V, Elenitoba-Johnson KS, Nesvizhskii AI, Ceron J, Lee CY, Borggrefe T, Kovall RA, Rual JF.

EMBO J. 2017 Nov 2;36(21):3232-3249. doi: 10.15252/embj.201796525. Epub 2017 Oct 13.

9.

A Naturally Generated Decoy of the Prostate Apoptosis Response-4 Protein Overcomes Therapy Resistance in Tumors.

Hebbar N, Burikhanov R, Shukla N, Qiu S, Zhao Y, Elenitoba-Johnson KSJ, Rangnekar VM.

Cancer Res. 2017 Aug 1;77(15):4039-4050. doi: 10.1158/0008-5472.CAN-16-1970. Epub 2017 Jun 16.

10.

Functional proteogenomics reveals biomarkers and therapeutic targets in lymphomas.

Rolland DCM, Basrur V, Jeon YK, McNeil-Schwalm C, Fermin D, Conlon KP, Zhou Y, Ng SY, Tsou CC, Brown NA, Thomas DG, Bailey NG, Omenn GS, Nesvizhskii AI, Root DE, Weinstock DM, Faryabi RB, Lim MS, Elenitoba-Johnson KSJ.

Proc Natl Acad Sci U S A. 2017 Jun 20;114(25):6581-6586. doi: 10.1073/pnas.1701263114. Epub 2017 Jun 12.

11.

Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Hematolymphoid Tumours.

Brown NA, Elenitoba-Johnson KS.

Head Neck Pathol. 2017 Mar;11(1):96-109. doi: 10.1007/s12105-017-0802-5. Epub 2017 Feb 28.

12.

International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.

Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, Simpson D, Liu AY, Menke D, Chandrakasan S, Lechowicz MJ, Wong RS, Pierson S, Paessler M, Rossi JF, Ide M, Ruth J, Croglio M, Suarez A, Krymskaya V, Chadburn A, Colleoni G, Nasta S, Jayanthan R, Nabel CS, Casper C, Dispenzieri A, Fosså A, Kelleher D, Kurzrock R, Voorhees P, Dogan A, Yoshizaki K, van Rhee F, Oksenhendler E, Jaffe ES, Elenitoba-Johnson KS, Lim MS.

Blood. 2017 Mar 23;129(12):1646-1657. doi: 10.1182/blood-2016-10-746933. Epub 2017 Jan 13.

13.

A new molecular paradigm in mycosis fungoides and Sézary syndrome.

Elenitoba-Johnson KS, Wilcox R.

Semin Diagn Pathol. 2017 Jan;34(1):15-21. doi: 10.1053/j.semdp.2016.11.002. Epub 2016 Dec 7. Review.

PMID:
28024703
14.

FBXO11: a novel germinal center B-cell regulator?

Elenitoba-Johnson KS.

Blood. 2016 Aug 4;128(5):611-2. doi: 10.1182/blood-2016-06-717496. No abstract available.

15.

Activating KRAS mutations are characteristic of oncocytic sinonasal papilloma and associated sinonasal squamous cell carcinoma.

Udager AM, McHugh JB, Betz BL, Montone KT, Livolsi VA, Seethala RR, Yakirevich E, Iwenofu OH, Perez-Ordonez B, DuRoss KE, Weigelin HC, Lim MS, Elenitoba-Johnson KS, Brown NA.

J Pathol. 2016 Aug;239(4):394-8. doi: 10.1002/path.4750. Epub 2016 Jul 1.

16.

Precision Medicine for Diffuse Large B-cell Lymphoma.

Lim MS, Elenitoba-Johnson KS.

Clin Cancer Res. 2016 Jun 15;22(12):2829-31. doi: 10.1158/1078-0432.CCR-16-0232. Epub 2016 Mar 17.

17.

API2-MALT1 oncoprotein promotes lymphomagenesis via unique program of substrate ubiquitination and proteolysis.

Rosebeck S, Lim MS, Elenitoba-Johnson KS, McAllister-Lucas LM, Lucas PC.

World J Biol Chem. 2016 Feb 26;7(1):128-37. doi: 10.4331/wjbc.v7.i1.128. Review.

18.

EGFR mutations in sinonasal squamous tumors: oncogenic and therapeutic implications.

Udager AM, McHugh JB, Elenitoba-Johnson KS, Brown NA.

Oncoscience. 2015 Nov 19;2(11):908-9. eCollection 2015. No abstract available.

19.

Next-generation IgVH sequencing CLL-like monoclonal B-cell lymphocytosis reveals frequent oligoclonality and ongoing hypermutation.

Klinger M, Zheng J, Elenitoba-Johnson KS, Perkins SL, Faham M, Bahler DW.

Leukemia. 2016 May;30(5):1055-61. doi: 10.1038/leu.2015.351. Epub 2015 Dec 21.

PMID:
26686246
20.

The PIAS-like Coactivator Zmiz1 Is a Direct and Selective Cofactor of Notch1 in T Cell Development and Leukemia.

Pinnell N, Yan R, Cho HJ, Keeley T, Murai MJ, Liu Y, Alarcon AS, Qin J, Wang Q, Kuick R, Elenitoba-Johnson KS, Maillard I, Samuelson LC, Cierpicki T, Chiang MY.

Immunity. 2015 Nov 17;43(5):870-83. doi: 10.1016/j.immuni.2015.10.007. Epub 2015 Oct 27.

21.

Mature T-cell leukemias: Molecular and Clinical Aspects.

Bailey NG, Elenitoba-Johnson KS.

Curr Hematol Malig Rep. 2015 Dec;10(4):421-8. doi: 10.1007/s11899-015-0288-8. Review.

PMID:
26433891
22.

Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome.

Kiel MJ, Sahasrabuddhe AA, Rolland DC, Velusamy T, Chung F, Schaller M, Bailey NG, Betz BL, Miranda RN, Porcu P, Byrd JC, Medeiros LJ, Kunkel SL, Bahler DW, Lim MS, Elenitoba-Johnson KS.

Nat Commun. 2015 Sep 29;6:8470. doi: 10.1038/ncomms9470.

23.

Aberrant expression of napsin A in a subset of malignant lymphomas.

Nam SJ, Kim S, Kim JE, Lim MS, Elenitoba-Johnson KS, Kim CW, Jeon YK.

Histol Histopathol. 2016 Feb;31(2):213-21. doi: 10.14670/HH-11-669. Epub 2015 Sep 24.

PMID:
26400099
24.

The role of aberrant proteolysis in lymphomagenesis.

Sahasrabuddhe AA, Elenitoba-Johnson KS.

Curr Opin Hematol. 2015 Jul;22(4):369-78. doi: 10.1097/MOH.0000000000000156. Review.

25.

High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted Sinonasal Papilloma.

Udager AM, Rolland DCM, McHugh JB, Betz BL, Murga-Zamalloa C, Carey TE, Marentette LJ, Hermsen MA, DuRoss KE, Lim MS, Elenitoba-Johnson KSJ, Brown NA.

Cancer Res. 2015 Jul 1;75(13):2600-2606. doi: 10.1158/0008-5472.CAN-15-0340. Epub 2015 Apr 30.

26.

Conversion of the LIMA1 tumour suppressor into an oncogenic LMO-like protein by API2-MALT1 in MALT lymphoma.

Nie Z, Du MQ, McAllister-Lucas LM, Lucas PC, Bailey NG, Hogaboam CM, Lim MS, Elenitoba-Johnson KS.

Nat Commun. 2015 Jan 8;6:5908. doi: 10.1038/ncomms6908.

PMID:
25569716
27.

Evaluation of allele-specific PCR and immunohistochemistry for the detection of BRAF V600E mutations in hairy cell leukemia.

Brown NA, Betz BL, Weigelin HC, Elenitoba-Johnson KS, Lim MS, Bailey NG.

Am J Clin Pathol. 2015 Jan;143(1):89-99. doi: 10.1309/AJCPDN4Q1JTFGCFC.

PMID:
25511147
28.

Role of the ubiquitin proteasome system in hematologic malignancies.

Sahasrabuddhe AA, Elenitoba-Johnson KS.

Immunol Rev. 2015 Jan;263(1):224-39. doi: 10.1111/imr.12236. Review.

29.

A clinical grade sequencing-based assay for CEBPA mutation testing: report of a large series of myeloid neoplasms.

Behdad A, Weigelin HC, Elenitoba-Johnson KS, Betz BL.

J Mol Diagn. 2015 Jan;17(1):76-84. doi: 10.1016/j.jmoldx.2014.09.007. Epub 2014 Nov 6. Erratum in: J Mol Diagn. 2015 Mar;17(2):206.

PMID:
25468431
30.

Intrinsic disorder drives N-terminal ubiquitination by Ube2w.

Vittal V, Shi L, Wenzel DM, Scaglione KM, Duncan ED, Basrur V, Elenitoba-Johnson KS, Baker D, Paulson HL, Brzovic PS, Klevit RE.

Nat Chem Biol. 2015 Jan;11(1):83-9. doi: 10.1038/nchembio.1700. Epub 2014 Dec 1.

31.

A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders.

Velusamy T, Kiel MJ, Sahasrabuddhe AA, Rolland D, Dixon CA, Bailey NG, Betz BL, Brown NA, Hristov AC, Wilcox RA, Miranda RN, Medeiros LJ, Jeon YK, Inamdar KV, Lim MS, Elenitoba-Johnson KS.

Blood. 2014 Dec 11;124(25):3768-71. doi: 10.1182/blood-2014-07-588434. Epub 2014 Oct 27.

32.

Fbxo45 inhibits calcium-sensitive proteolysis of N-cadherin and promotes neuronal differentiation.

Chung FZ, Sahasrabuddhe AA, Ma K, Chen X, Basrur V, Lim MS, Elenitoba-Johnson KS.

J Biol Chem. 2014 Oct 10;289(41):28448-59. doi: 10.1074/jbc.M114.561241. Epub 2014 Aug 20.

33.

Activating FGFR2-RAS-BRAF mutations in ameloblastoma.

Brown NA, Rolland D, McHugh JB, Weigelin HC, Zhao L, Lim MS, Elenitoba-Johnson KS, Betz BL.

Clin Cancer Res. 2014 Nov 1;20(21):5517-26. doi: 10.1158/1078-0432.CCR-14-1069. Epub 2014 Jul 3.

34.

Fbxo45-mediated degradation of the tumor-suppressor Par-4 regulates cancer cell survival.

Chen X, Sahasrabuddhe AA, Szankasi P, Chung F, Basrur V, Rangnekar VM, Pagano M, Lim MS, Elenitoba-Johnson KS.

Cell Death Differ. 2014 Oct;21(10):1535-45. doi: 10.1038/cdd.2014.92. Epub 2014 Jul 4.

35.

High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.

Brown NA, Furtado LV, Betz BL, Kiel MJ, Weigelin HC, Lim MS, Elenitoba-Johnson KS.

Blood. 2014 Sep 4;124(10):1655-8. doi: 10.1182/blood-2014-05-577361. Epub 2014 Jun 30.

36.

Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia.

Kiel MJ, Velusamy T, Rolland D, Sahasrabuddhe AA, Chung F, Bailey NG, Schrader A, Li B, Li JZ, Ozel AB, Betz BL, Miranda RN, Medeiros LJ, Zhao L, Herling M, Lim MS, Elenitoba-Johnson KS.

Blood. 2014 Aug 28;124(9):1460-72. doi: 10.1182/blood-2014-03-559542. Epub 2014 May 13.

37.

Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas.

Rolland D, Basrur V, Conlon K, Wolfe T, Fermin D, Nesvizhskii AI, Lim MS, Elenitoba-Johnson KS.

Am J Pathol. 2014 May;184(5):1331-42. doi: 10.1016/j.ajpath.2014.01.036. Epub 2014 Mar 22.

38.

Requisite analytic and diagnostic performance characteristics for the clinical detection of BRAF V600E in hairy cell leukemia: a comparison of 2 allele-specific PCR assays.

Brown NA, Weigelin HC, Bailey N, Laliberte J, Elenitoba-Johnson KS, Lim MS, Betz BL.

Appl Immunohistochem Mol Morphol. 2015 Sep;23(8):590-600. doi: 10.1097/PAI.0000000000000024.

PMID:
24503706
39.

Oncogenic Y641 mutations in EZH2 prevent Jak2/β-TrCP-mediated degradation.

Sahasrabuddhe AA, Chen X, Chung F, Velusamy T, Lim MS, Elenitoba-Johnson KS.

Oncogene. 2015 Jan 22;34(4):445-54. doi: 10.1038/onc.2013.571. Epub 2014 Jan 27.

PMID:
24469040
40.

Molecular diagnostics of T-cell lymphoproliferative disorders.

Bailey NG, Elenitoba-Johnson KS.

Cancer J. 2014 Jan-Feb;20(1):48-60. doi: 10.1097/PPO.0000000000000016. Review.

PMID:
24445765
41.

Detection of MPL mutations by a novel allele-specific PCR-based strategy.

Furtado LV, Weigelin HC, Elenitoba-Johnson KS, Betz BL.

J Mol Diagn. 2013 Nov;15(6):810-8. doi: 10.1016/j.jmoldx.2013.07.006. Epub 2013 Aug 28.

PMID:
23994117
42.

Fusion peptides from oncogenic chimeric proteins as putative specific biomarkers of cancer.

Conlon KP, Basrur V, Rolland D, Wolfe T, Nesvizhskii AI, MacCoss MJ, Lim MS, Elenitoba-Johnson KS.

Mol Cell Proteomics. 2013 Oct;12(10):2714-23. doi: 10.1074/mcp.M113.029926. Epub 2013 Jul 8.

43.

Integrated phosphoproteomic and metabolomic profiling reveals NPM-ALK-mediated phosphorylation of PKM2 and metabolic reprogramming in anaplastic large cell lymphoma.

McDonnell SR, Hwang SR, Rolland D, Murga-Zamalloa C, Basrur V, Conlon KP, Fermin D, Wolfe T, Raskind A, Ruan C, Jiang JK, Thomas CJ, Hogaboam CM, Burant CF, Elenitoba-Johnson KS, Lim MS.

Blood. 2013 Aug 8;122(6):958-68. doi: 10.1182/blood-2013-01-482026. Epub 2013 Jun 27.

44.

A multiplexed fragment analysis-based assay for detection of JAK2 exon 12 mutations.

Furtado LV, Weigelin HC, Elenitoba-Johnson KS, Betz BL.

J Mol Diagn. 2013 Sep;15(5):592-9. doi: 10.1016/j.jmoldx.2013.04.006. Epub 2013 Jun 28.

PMID:
23810504
45.

The ubiquitin-conjugating enzyme (E2) Ube2w ubiquitinates the N terminus of substrates.

Scaglione KM, Basrur V, Ashraf NS, Konen JR, Elenitoba-Johnson KS, Todi SV, Paulson HL.

J Biol Chem. 2013 Jun 28;288(26):18784-8. doi: 10.1074/jbc.C113.477596. Epub 2013 May 21.

46.

Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia.

Velusamy T, Palanisamy N, Kalyana-Sundaram S, Sahasrabuddhe AA, Maher CA, Robinson DR, Bahler DW, Cornell TT, Wilson TE, Lim MS, Chinnaiyan AM, Elenitoba-Johnson KS.

Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):3035-40. doi: 10.1073/pnas.1214326110. Epub 2013 Feb 4.

47.

MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC.

Min DJ, Ezponda T, Kim MK, Will CM, Martinez-Garcia E, Popovic R, Basrur V, Elenitoba-Johnson KS, Licht JD.

Leukemia. 2013 Mar;27(3):686-94. doi: 10.1038/leu.2012.269. Epub 2012 Sep 13.

48.

Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma.

Kiel MJ, Velusamy T, Betz BL, Zhao L, Weigelin HG, Chiang MY, Huebner-Chan DR, Bailey NG, Yang DT, Bhagat G, Miranda RN, Bahler DW, Medeiros LJ, Lim MS, Elenitoba-Johnson KS.

J Exp Med. 2012 Aug 27;209(9):1553-65. doi: 10.1084/jem.20120910. Epub 2012 Aug 13.

49.

Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.

Hummel JM, Kletecka MC, Sanks JK, Chiselite MD, Roulston D, Smith LB, Czuchlewski DR, Elenitoba-Johnson KS, Lim MS.

Diagn Mol Pathol. 2012 Sep;21(3):176-83. doi: 10.1097/PDM.0b013e318246975e.

PMID:
22847163
50.

Conjugated polyelectrolyte-antibody hybrid materials for highly fluorescent live cell-imaging.

Lee K, Lee J, Jeong EJ, Kronk A, Elenitoba-Johnson KS, Lim MS, Kim J.

Adv Mater. 2012 May 8;24(18):2479-84. doi: 10.1002/adma.201103895. Epub 2012 Apr 10.

Supplemental Content

Loading ...
Support Center